JP2509271B2 - 遺伝子修飾され生体内で増殖された真核宿主細胞における誘導発現機構によるタンパク質の生産方法 - Google Patents
遺伝子修飾され生体内で増殖された真核宿主細胞における誘導発現機構によるタンパク質の生産方法Info
- Publication number
- JP2509271B2 JP2509271B2 JP62506060A JP50606087A JP2509271B2 JP 2509271 B2 JP2509271 B2 JP 2509271B2 JP 62506060 A JP62506060 A JP 62506060A JP 50606087 A JP50606087 A JP 50606087A JP 2509271 B2 JP2509271 B2 JP 2509271B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- gene
- plasmid
- medium
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 18
- 230000014509 gene expression Effects 0.000 title claims abstract description 17
- 230000001939 inductive effect Effects 0.000 title claims abstract description 9
- 238000001727 in vivo Methods 0.000 title abstract description 4
- 230000007246 mechanism Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 121
- 239000002609 medium Substances 0.000 claims description 48
- 238000011580 nude mouse model Methods 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 39
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 32
- 241000699660 Mus musculus Species 0.000 claims description 31
- 239000013612 plasmid Substances 0.000 claims description 29
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 28
- 239000000854 Human Growth Hormone Substances 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 26
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 239000012679 serum free medium Substances 0.000 claims description 18
- 238000011081 inoculation Methods 0.000 claims description 15
- 238000011654 sencar mouse Methods 0.000 claims description 15
- 241000701822 Bovine papillomavirus Species 0.000 claims description 12
- 229960004927 neomycin Drugs 0.000 claims description 12
- 230000035939 shock Effects 0.000 claims description 12
- 229930193140 Neomycin Natural products 0.000 claims description 11
- 108700020796 Oncogene Proteins 0.000 claims description 11
- 101150074155 DHFR gene Proteins 0.000 claims description 9
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 claims description 7
- 101150031823 HSP70 gene Proteins 0.000 claims description 7
- 101150052825 dnaK gene Proteins 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 5
- 102000043276 Oncogene Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 231100000590 oncogenic Toxicity 0.000 claims description 4
- 230000002246 oncogenic effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000012761 co-transfection Methods 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000007248 cellular mechanism Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 239000012090 serum-supplement Substances 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 230000029087 digestion Effects 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LEIXEEFBKOMCEQ-AFJQJTPPSA-N (9z,12z)-heptadeca-9,12-dienoic acid Chemical compound CCCC\C=C/C\C=C/CCCCCCCC(O)=O LEIXEEFBKOMCEQ-AFJQJTPPSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102220201851 rs143406017 Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101000932768 Conus catus Alpha-conotoxin CIC Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010090813 Drosophila ubiquitin specific protease 36 Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001319148 Pharmacis Species 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000001850 polyploid cell Anatomy 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP86810455A EP0263908B1 (en) | 1986-10-15 | 1986-10-15 | Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo |
| AT86810455.5 | 1986-10-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01501439A JPH01501439A (ja) | 1989-05-25 |
| JP2509271B2 true JP2509271B2 (ja) | 1996-06-19 |
Family
ID=8196470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62506060A Expired - Lifetime JP2509271B2 (ja) | 1986-10-15 | 1987-10-12 | 遺伝子修飾され生体内で増殖された真核宿主細胞における誘導発現機構によるタンパク質の生産方法 |
Country Status (12)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85728A (en) * | 1987-03-25 | 1993-01-14 | Bio Mega Inc | Fluorine containing atrial natriuretic peptides, their preparation and pharmaceutical compositions containing them |
| JP2796547B2 (ja) * | 1987-09-11 | 1998-09-10 | ジェネンテク，インコーポレイテッド | 組換え細胞培養中でのポリペプチド発現の増大法 |
| WO1989005864A1 (en) * | 1987-12-15 | 1989-06-29 | The Trustees Of Princeton University | Transgenic testing systems for mutagens and carcinogens |
| ZA892518B (en) * | 1988-04-08 | 1989-12-27 | Intracel Corp | Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells |
| EP0386185A1 (fr) * | 1988-07-29 | 1990-09-12 | IntraCel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| GB8928884D0 (en) * | 1989-12-21 | 1990-02-28 | Feldmann Marc | Transformed cell lines |
| GB9003791D0 (en) * | 1990-02-20 | 1990-04-18 | Ludwig Inst Cancer Res | Transgenic animals,cell lines therefrom,and their use |
| US5866759A (en) * | 1991-02-20 | 1999-02-02 | Ludwig Institute For Cancer Research | Transgenic mice expressing TSSV40 large T antigen |
| US5877398A (en) * | 1993-01-29 | 1999-03-02 | University Of British Columbia | Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology |
| EP0922110B1 (en) * | 1996-08-15 | 2008-04-16 | The Government of the United States of America, represented by the Secretary, Department of Health and Human Services | Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat |
| IT1294450B1 (it) * | 1997-08-28 | 1999-03-25 | Consiglio Nazionale Ricerche | Animali transgenici per lo studio di agenti tossici chimici fisici o biologici |
| US7098191B2 (en) * | 1997-11-03 | 2006-08-29 | The Arizona Board Of Reagents | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| US6709858B1 (en) * | 1997-11-03 | 2004-03-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| US7279565B2 (en) * | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| AUPQ233799A0 (en) * | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
| US20030044398A1 (en) * | 2001-03-20 | 2003-03-06 | Robl James M. | Methods for producing antibodies in mammals |
| CA2349506C (en) * | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| EP1797186B1 (en) * | 2004-10-04 | 2016-05-25 | National Research Council Of Canada | Expression system, components thereof and methods of use |
| US7935788B2 (en) * | 2004-10-04 | 2011-05-03 | National Research Council Of Canada | Reverse cumate repressor mutant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| JPS5729294A (en) * | 1980-07-30 | 1982-02-17 | Hayashibara Biochem Lab Inc | Preparation of human insulin |
| JPS5852634B2 (ja) * | 1980-12-05 | 1983-11-24 | 株式会社林原生物化学研究所 | ウロキナ−ゼの製造法 |
| DK172882B1 (da) * | 1983-02-07 | 1999-09-06 | Rothwell Property Ltd | DNA indeholdende udtrykkelseskontrolregion fra et eukaryot varmechokproteingen, vektor og eukaryot celle indeholdende DNA'e |
| AU7280487A (en) * | 1986-04-04 | 1987-10-20 | Battelle Memorial Institute | Methods and compositions for expression of competent eukaryotic gene products |
| EP0262942A1 (en) * | 1986-09-30 | 1988-04-06 | Smithkline Beecham Corporation | Cell transfection |
| DE3855681T2 (de) * | 1987-05-01 | 1997-05-28 | The General Hospital Corp., Boston, Mass. | Transkaryotische Einpflanzung |
-
1986
- 1986-10-15 EP EP86810455A patent/EP0263908B1/en not_active Expired - Lifetime
- 1986-10-15 ES ES198686810455T patent/ES2038602T3/es not_active Expired - Lifetime
- 1986-10-15 AT AT86810455T patent/ATE67787T1/de not_active IP Right Cessation
- 1986-10-15 DE DE86810455T patent/DE3681738D1/de not_active Expired - Lifetime
-
1987
- 1987-10-12 AU AU80784/87A patent/AU612607B2/en not_active Ceased
- 1987-10-12 WO PCT/EP1987/000599 patent/WO1988002778A1/en not_active Application Discontinuation
- 1987-10-12 JP JP62506060A patent/JP2509271B2/ja not_active Expired - Lifetime
- 1987-10-12 EP EP87906742A patent/EP0285642A1/en not_active Withdrawn
- 1987-10-12 ZA ZA877656A patent/ZA877656B/xx unknown
- 1987-10-14 CA CA000549217A patent/CA1319631C/en not_active Expired - Fee Related
-
1988
- 1988-06-03 NO NO882469A patent/NO882469D0/no unknown
- 1988-06-13 DK DK320888A patent/DK320888D0/da not_active Application Discontinuation
-
1995
- 1995-04-13 US US08/421,277 patent/US5614381A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU8078487A (en) | 1988-05-06 |
| DK320888A (da) | 1988-06-13 |
| EP0263908B1 (en) | 1991-09-25 |
| EP0285642A1 (en) | 1988-10-12 |
| ZA877656B (en) | 1988-04-18 |
| US5614381A (en) | 1997-03-25 |
| EP0263908A1 (en) | 1988-04-20 |
| DE3681738D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-10-31 |
| CA1319631C (en) | 1993-06-29 |
| DK320888D0 (da) | 1988-06-13 |
| JPH01501439A (ja) | 1989-05-25 |
| WO1988002778A1 (en) | 1988-04-21 |
| AU612607B2 (en) | 1991-07-18 |
| NO882469L (no) | 1988-06-03 |
| NO882469D0 (no) | 1988-06-03 |
| ATE67787T1 (de) | 1991-10-15 |
| ES2038602T3 (es) | 1993-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2509271B2 (ja) | 遺伝子修飾され生体内で増殖された真核宿主細胞における誘導発現機構によるタンパク質の生産方法 | |
| JP3333902B2 (ja) | 遺伝子導入動物、それから得られる細胞および細胞系、およびその使用 | |
| JP5441288B2 (ja) | 細胞の無タンパク質かつ無血清の培養のための培地 | |
| EP0521586B1 (en) | recombinant FSH | |
| JPH0832244B2 (ja) | ヘテロポリマ−系蛋白質 | |
| Barski et al. | Malignant transformation in vitro of cells from C57BL mouse normal pulmonary tissue | |
| EP0485689B1 (en) | Cells growing in protein-free medium, and enhancing replication of exogenous genes | |
| CN116640231B (zh) | 一种重组人源化17型胶原多肽及其制备方法 | |
| ES2267280T3 (es) | Clon celular recombinante estable, su preparacion y utilizacion del mismo. | |
| EP0207147A4 (en) | METHOD OF ELECTRICAL IMMORTALIZATION OF LYMPHOID CELLS. | |
| CN102586190B (zh) | 高效表达重组人神经生长因子的cho细胞株及其构建方法 | |
| JP4671504B2 (ja) | 正常ヒト皮膚組織由来の不死化した細胞系 | |
| PT901522E (pt) | Células aviárias imortais | |
| CN102876700B (zh) | PiggyBac转座子介导的肌肉特异表达A-FABP通用载体构建 | |
| LU507631B1 (en) | Crispr/cas9-grna targeting plasmid, donor plasmid, and preparation method for immortalized mouse cell line | |
| CN117106724A (zh) | 一种h3k27m突变型脊髓胶质瘤细胞及其培养方法 | |
| KR960007195B1 (ko) | 이종유전자의 발현을 증대시킬 수 있는 재조합 플라스미드 및 형질전환세포의 제조방법, 및 그 형질전환 세포를 이용한 펩타이드의 제조방법 | |
| EP0162319B1 (en) | Method of joining heterologous genes | |
| Asselin et al. | Mutation in the polyomavirus genome that activates the properties of large T associated with neoplastic transformation | |
| US4477567A (en) | Continuous bovine beta cell line | |
| CN118184766A (zh) | 一种近天然提取胶原的重组人源化iii型胶原蛋白制备方法 | |
| Ferguson et al. | Isolation and long-term culture of diploid mammalian cell lines | |
| CN111893137A (zh) | 一种在三角褐指藻中表达透明颤菌血红蛋白用于自养和兼养培养的方法 | |
| Dreano et al. | Production of secretable proteins using the passage in vivo as tumours of cells carrying heat-inducible expression constructs | |
| CN116496992A (zh) | 一种鸡胚成肌永生化细胞及其构建方法和应用 |